Premium
Polydisulfide manganese(II) complexes as non‐gadolinium biodegradable macromolecular MRI contrast agents
Author(s) -
Ye Zhen,
Jeong EunKee,
Wu Xueming,
Tan Mingqian,
Yin Shouyu,
Lu ZhengRong
Publication year - 2012
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.22848
Subject(s) - cystamine , manganese , gadolinium , copolymer , chemistry , mri contrast agent , macromolecule , magnetic resonance imaging , contrast (vision) , terpyridine , biochemistry , medicine , metal , radiology , organic chemistry , polymer , artificial intelligence , computer science
Purpose: To develop safe and effective manganese(II) ‐based biodegradable macromolecular MRI contrast agents. Materials and Methods: In this study, we synthesized and characterized two polydisulfide manganese(II) complexes, Mn‐DTPA cystamine copolymers and Mn‐EDTA cystamine copolymers, as new biodegradable macromolecular MRI contrast agents. The contrast enhancement of the two manganese‐based contrast agents were evaluated in mice bearing MDA‐MB‐231 human breast carcinoma xenografts, in comparison with MnCl 2 . Results: The T 1 and T 2 relaxivities were 4.74 and 10.38 mM −1 s −1 per manganese at 3T for Mn‐DTPA cystamine copolymers (M n = 30.50 kDa) and 6.41 and 9.72 mM −1 s −1 for Mn‐EDTA cystamine copolymers (M n = 61.80 kDa). Both polydisulfide Mn(II) complexes showed significant liver, myocardium and tumor enhancement. Conclusion: The manganese‐based polydisulfide contrast agents have a potential to be developed as alternative non‐gadolinium contrast agents for MR cancer and myocardium imaging. J. Magn. Reson. Imaging 2012;35:737‐744. © 2011 Wiley Periodicals, Inc.